United Therapeutics CorporationUTHRNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Financials Growth Insiders

Latest News

businesswire.com

United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide a company overview and update on Monday, March 9, 2026, from 1:00 to 1:30 p.m. EDT, at the Leerink Global Healthcare Conference in Miami Beach. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An.

seekingalpha.com

United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

seekingalpha.com

United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript

reuters.com

United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study

United Therapeutics said on Monday its experimental pill for a type of blood pressure disorder met all the main and secondary goals of a late-stage study.

businesswire.com

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its long-term pivotal phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.62]; p

defenseworld.net

Andra AP fonden Reduces Stock Position in United Therapeutics Corporation $UTHR

Andra AP fonden lowered its holdings in United Therapeutics Corporation (NASDAQ: UTHR) by 37.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 73,800 shares of the biotechnology company's stock after selling 44,600 shares during the quarter. Andra AP fonden owned approximately 0.17%

benzinga.com

These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings

United Therapeutics Corp (NASDAQ: UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.

seekingalpha.com

United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management Team

United Therapeutics Corporation delivered strong Q4 and FY2025 results, with revenues up 10%+ and net income per share up ~14%, driving a >75% stock rally. UTHR's Tyvaso remains the dominant PAH franchise, with robust growth and new product innovations like Tresmi and ralinepag poised to reinforce market leadership. Major data catalysts in PAH (ralinepag Phase 3) and IPF (TETON-1/2) could unlock billion-dollar opportunities and further accelerate UTHR's revenue trajectory.

zacks.com

UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance

United Therapeutics Q4 earnings beat estimates, Tyvaso DPI sales jump 24% despite revenue miss.

defenseworld.net

2,341 Shares in United Therapeutics Corporation $UTHR Purchased by Empirical Asset Management LLC

Empirical Asset Management LLC acquired a new stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,341 shares of the biotechnology company's stock, valued at approximately $981,000. Other institutional investors have also made

defenseworld.net

United Therapeutics Q4 Earnings Call Highlights

United Therapeutics (NASDAQ: UTHR) used its fourth-quarter 2025 corporate update webcast to highlight what executives described as a set of near-term product and clinical milestones aimed at reshaping its pulmonary hypertension and interstitial lung disease franchises, while also reiterating confidence in sustained revenue growth and outlining progress in its organ manufacturing and transplantation programs. New inhaler

zacks.com

Compared to Estimates, United Therapeutics (UTHR) Q4 Earnings: A Look at Key Metrics

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com

United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $7.7 per share, beating the Zacks Consensus Estimate of $6.78 per share. This compares to earnings of $6.19 per share a year ago.

seekingalpha.com

United Therapeutics Corporation (UTHR) Q4 2025 Earnings Call Transcript

businesswire.com

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. “As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation.

defenseworld.net

United Therapeutics Corporation $UTHR Shares Sold by Chase Investment Counsel Corp

Chase Investment Counsel Corp reduced its holdings in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 23.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,400 shares of the biotechnology company's stock after selling 1,375 shares during the period. Chase

gurufocus.com

Bernard Horn's Strategic Moves: Exiting The Carlyle Group Inc with a -1.68% Impact

Exploring the Investment Decisions of a Seasoned Guru Bernard Horn (Trades, Portfolio) recently submitted the N-PORT filing for the fourth quarter of 2025, pro

zacks.com

USNA or UTHR: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with USANA Health Sciences (USNA) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?

businesswire.com

United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide a company overview and update on Monday, March 2, 2026, from 2:30 to 3:00 p.m. EST, at the TD Cowen 46th Annual Health Care Conference in Boston. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An arch.

defenseworld.net

Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $476.34, for a total value of $3,953,622.00. Following the sale, the executive vice president directly owned 36,781 shares of the company's

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance